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ABSTRACT 
 
Insulin-like growth factors (IGF-I and IGF-II) are potent metabolic and mitogenic proteins 
with functions in glucose and lipid metabolism as well as cell growth, differentiation and 
apoptosis. Their activity is controlled by binding proteins (IGFBPs), which also have IGF-
independent cell functions. SHBG is another multifunctional protein with direct cell actions 
as well as binding protein functions. 
 
The aim of the in vitro study was to investigate the hepatic regulation of IGFBPs and SHBG 
using hepatoma cell cultures as experimental models. Insulin and IGFs inhibited IGFBP-1 and 
SHBG production equipotentially. Estradiol did not affect IGFBP-1 production, but 
stimulated that of SHBG. Insulin, IGF-I and IGF-II stimulated and cortisol inhibited IGFBP-3 
production, whereas sex hormones had no effect at physiological concentrations. 
 
Being liver-derived proteins downregulated by insulin, IGFBP-1 and SHBG could serve as 
indicators of metabolic syndrome and hyperinsulinemia-related cardiovascular risk. Hence 
circulating concentrations of SHBG and IGFBP-1 were measured in 335 elderly men. 
Subjects with metabolic syndrome or abnormal glucose tolerance had low serum SHBG and 
IGFBP-1 concentrations, but diabetics only low SHBG levels. SHBG was less influenced by 
BMI than IGFBP-1. Low SHBG levels indicated increased cardiovascular mortality, whereas 
those of IGFBP-1 had no association with mortality. In women with preterm rupture of 
membranes and subsequent delivery, serum IGF-I and IGFBP-3 levels did not differ from 
those in controls. 
 
In conclusion, in in vitro conditions, insulin inhibits IGFPB-1 and SHBG production and 
stimulates IGFPB-3 production in hepatoma cells. Men with low serum SHBG levels had 
increased cardiovascular mortality, suggesting a possible role of insulin. In women with 
premature delivery, IGF-1 and the major carrier IGFPB-3 do not play a role in prediction of 
outcome. 
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INTRODUCTION 
 
Insulin-like growth factors (IGFs) and the major modulators of their actions, insulin-like 
growth factor binding proteins (IGFBPs), as well as SHBG, have become the subjects of 
renewed interest in recent years. IGFBP-1, IGFBP-3 and SHBG are proteins that were long 
thought to be simple carrier proteins for IGFs and sex hormones, respectively. The new 
awareness of IGFBPs has arisen as a result of reports demonstrating that they exhibit a 
multitude of cellular actions that appear to be independent of their IGF-binding functions 
(Rosenzweig 2004). SHBG has been found to participate in steroid signaling at the cell 
membrane and local modification of steroid hormone effects (Kahn et al. 2002). IGFBPs and 
SHBG are proteins mainly produced by the liver, but widely expressed in human tissues. 
They have been found to be multifunctional proteins with roles in glucose metabolism, cell 
growth and proliferation, the reproductive system, and cardiovascular and cancer risks 
(Rutanen et al. 2000, Kahn et al. 2002, Renehan et al. 2004, Rosenzweig 2004). 
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REVIEW OF THE LITERATURE 
 
 
1. THE INSULIN-LIKE GROWTH FACTOR (IGF) SYSTEM 
 
The IGF family consists of growth factors (IGF-I and IGF-II), specific receptors (IGF-IR, 
IGF-IIR, IR and hybrid receptors) and binding proteins (IGFBPs) (Jones and Clemmons 
1995). The IGFBPs are divided into two groups: high-affinity binding proteins (IGFBP-1 to -
6) and low-affinity IGFBP-related proteins (IGFBP-rP1 to -rP4 or IGFBP-7 to -10) (Kim et 
al. 1997). 
 
 
2. IGF-I AND IGF-II 
 
IGF-I and -II are small single chain peptides that are structurally related to proinsulin. They 
consist of 70 and 67 amino acids, respectively, with 70% reciprocal homology in humans 
(Rinderknecht and Humbel 1978a,b). These growth factors, previously designated as 
somatomedins (Daughaday et al. 1972), play many roles in paracrine and endocrine 
regulation of tissue growth, cell proliferation and differentiation, and apoptosis (Khandwala et 
al. 2000). In mammals they are encoded by large, complex, single copy genes. IGF mRNA or 
protein can be detected in every tissue examined at some developmental stage (Rechler 1990). 
IGF peptides occur in large concentrations in the circulation and have systemic, hormonal, 
and local paracrine effects on cell behavior. 
 
Growth hormone is the main hormonal regulator of circulating IGFs, but other factors such as 
nutritional status also affect IGF-I concentrations (Jones and Clemmons 1995). One group of 
regulating factors is the family of IGFBPs, of which IGFBP-3 binds 70–80%, and IGFBP-1 
binds 20–30% of IGF-I, leaving only about 10% of IGF-I free. IGF-I receptors are another 
component of the regulatory system affecting circulating IGF-I. Programmed cell death 
(apoptosis) can be prevented by IGF-I binding to its receptor (LeRoith et al. 1997). Another 
component of IGF-I regulation is the IGFBP protease system, comprising enzymes that cleave 
IGFBPs into smaller fragments, thereby altering their abilities to bind IGFs (Wetterau et al. 
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1999). Phosphorylation of IGFBPs also changes their affinity to IGFs (Jones et al. 1991, 
Westwood et al. 1997). 
 
IGFs differ functionally from insulin, being subject to long-term nutritional changes and not 
having acute variation in circulating levels. IGF-I has insulin-like metabolic actions; it plays 
important roles in regulating glucose metabolism, amino acid and free fatty acid uptake 
(Boulvare 1992) and the synthesis of various intra- and extracellular proteins such as 
collagens (Canalis 1980). Serum IGF-I concentrations are reduced in patients with type 1 
diabetes and are not normalized by insulin treatment (Holt et al. 2003). 
 
IGF-I and IGF-II stimulate growth by different mechanisms. Studies on knockout mice 
carrying null mutations of genes encoding IGFs or the IGF-I receptor (IGF IR) revealed that 
they exhibited severe growth deficiency with underdeveloped bone, muscle and lung tissues 
(Liu et al. 1993). The effects of IGF on the cell cycle consist of promotion of mitotic activity 
and cell differentiation, as well as inhibition of apoptosis (Jones and Clemmons 1995). High 
circulating IGF-I concentrations have been found to be associated with an increased risk of 
prostate, lung, colorectal and premenopausal breast cancer (Reheran et al. 2004). Individuals 
with high serum IGF-II levels also have an elevated risk of developing breast, prostate, colon 
and lung cancer. IGF-II is commonly expressed by tumor cells and may act as an autocrine 
growth factor (LeRoith et al. 2003). The IGF-I receptor is commonly overexpressed in many 
cancers, and many recent studies have revealed new signaling pathways emanating from the 
IGF-I receptor that affect cancer cell proliferation, adhesion, migration and cell death; 
functions that are critical for cancer cell survival and metastasis (LeRoith et al. 2003). 
Concentrations of IGFs  vary greatly between individuals, which might affect the distribution 
of cancer risk in a population (Pollak 2000). 
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Figure 1.  
A. Main regulatory factors of IGF actions: + = stimulatory effect; - = inhibitory effect 
B. Regulation of free IGF availability by IGFBP-1 and IGFBP-3: Lesser-phosphorylated isoforms of IGFBP-1 
have reduced affinity for IGF-I and thus are more bound to release. IGF-I and exert lesser inhibitory action. The 
ternary complex consisting of IGF-I, IGFBP-3and ALS releases free IGF-I after cleavage of IGFBP-3 by 
specific proteases in the vicinity of IGF receptors.  
C. IGF-I and IGF-II bind both to insulin receptor and IGF-IR. The main function of IGF-IIR is to facilitate 
clearance of IGF-II from circulation. 
(Modified from Kajantie 2003 with permission) 
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3. IGF RECEPTORS 
 
Most of the effects of the IGFs are mediated by binding to IGF-IR. The receptors for insulin 
and IGF-I are structurally similar, composed of extracellular α subunits that bind the ligands 
and β subunits that anchor the receptor to the membrane and contain tyrosine kinase activity 
in their cytoplasmic domains (Jones and Clemmons 1995). IGF-IR binds insulin with 
approximately 100- to 1000-fold lower affinity compared with IGF-I (Steele-Perkins et al. 
1988); thus only high concentrations of insulin bind to and activate IGF-IR (Chisalita et al. 
2004). The affinity of IGF-IR for IGF-II is 2- to 15-fold lower than for IGF-I. Insulin 
receptors (IRs) have high affinity for insulin and a 100-fold lower affinity for IGF-I (Steele-
Perkins et al. 1988, Germain et al. 1992). The insulin analog glargine has a 10-fold higher 
affinity for IGF-IR than human insulin (Chisalita et al. 2004). 
 
As there is close homology between the IGF-I and insulin receptors, hybrid insulin/IGF 
receptors may also be formed in tissues coexpressing IR and IGFI-R (Pandini et al. 2002). 
Insulin receptor αβ-half receptors dimerize with IGF-I αβ-half receptors in the presence of 
ligands (Treadway et al. 1992). Hybrids bind both IGF-I and IGF-II with similar affinities as 
classical IGF-I receptors, but insulin with decreased affinity (Soos et al. 1989). 
 
IGF-IIR is structurally unrelated to the other receptors in this family, having a short 
cytoplasmic tail and no tyrosine kinase activity (LeRoith et al. 1995). It is identical to 
mannose-6-phosphate (M6P) receptor, a protein involved in the intracellular lysosomal 
targeting of acid hydrolases and other mannosylated proteins (Morgan et al. 1987). IGF-IIR is 
thought to function primarily as a scavenger receptor, regulating the internalization and 
degradation of extracellular IGF-II, thus regulating circulating IGF-II levels (Khandwala et al. 
2000). The IGF-II receptor also regulates intracellular trafficking of lysosomal enzymes 
including cathepsin, which serves as an IGFBP proteolytic enzyme (Khandwala et al. 2000).  
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4. IGF BINDING PROTEINS (IGFBPS) 
 
IGFBPs bind both IGF-I and IGF-II with high affinity. IGFBP-encoding genes share a 
common structural organization, in which four conserved exons are located within genes 
ranging from 5 kb (IGFBP-1) to more than 30 kb (IGFBP-2 and IGFBP-5) (Baxter et al. 
1997). The IGFBPs share distinctive structural and functional characteristics. They contain 
three structurally distinct domains, each comprising approximately one-third of the 
molecule (Kiefer et al. 1991). All IGFBPs have cysteine-rich amino-terminal (N) and 
carboxyl-terminal (C) domains and less-conserved central regions (Brinkman et al. 1988a). 
Residues involved in IGF binding occur in both amino- and carboxyl-terminal domains, 
implying the existence of an IGF-binding pocket involving both domains (Firth and Baxter 
2002). Other important subdomains have been identified within the carboxyl-terminal 
regions of various IGFBPs. Arg-Gly-Asp (RGD) integrin-binding motifs are found in 
IGFBP-1 and -2. Motifs with heparin-binding activity in IGFBP-3 and -5 are also involved 
in interaction with the acid-labile subunit (ALS) and other ligands such as PAI-I and 
transferrin, and with cell and matrix binding and nuclear transport (Firth and Baxter 2002) 
The nonconserved central domain contains several sites of posttranslational modification: 
sites of N-linked glycosylation in IGFBP-3 and -4, phosphorylation sites in IGFBP-1, -3 
and -5 and proteolytic cleavage sites (Firth and Baxter 2002) (Figure 2). 
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Figure 2. Generalized diagram of IGFBP structure showing proposed interaction with IGF-I through both N 
and C domains. Functional domains and sites of posttranslational modification are indicated. (from Firth and 
Baxter 2002, published by  permission) 
 
 
 
 
 
The actions of IGFBPs can be divided into IGF-dependent and IGF-independent activities 
(Oh et al. 1993a). The IGF-dependent actions include: 1) transport of IGFs in plasma and 
other biological fluids, 2) increasing the half-life of IGF peptides and 3) modulating the 
access of IGF ligands to their receptors. IGF-independent actions refer to the ability of 
IGFBPs to regulate cell growth, migration or metabolism in manners independent of IGF 
action. IGF-independent actions presumably occur via direct interactions of the IGFBPs 
with cellular receptors or interacting proteins (Oh et al. 1993b). 
 
The six IGFBPs differ in their tissue expression and their regulation from other hormones 
and growth factors. Their effects are also influenced by posttranslational modifications, 
such as glycosylation, affecting cell interaction, phosphorylation, affecting IGF-binding 
affinity and susceptibility to proteases, and proteolysis, affecting both IGF-independent 
and IGF-dependent actions (Firth and Baxter 2002). 
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In addition to the six IGFBPs that bind IGFs with high affinity, four IGFBP-related 
proteins (IGFBP-rPs 1–4) have been identified (Kim et al. 1997). IGFBP-rP1 was formerly 
known as mac25, TAF or PSF; later as IGFBP-7. IGFBP-rPs 2–4 (CTGF, nov, cyr61) 
belong to the connective tissue growth factor family. They share the cysteine-rich N-
terminal region of classical IGFBPs, but not the conserved C-terminal domain required for 
optimal IGF binding (Baxter et al. 1998). Thus IGFBP-rPs bind IGFs with much lower 
affinity than IGFBPs. 
 
This review of the literature concentrates further on IGFBP-1 and -3, which are probably 
the most significant circulating IGFBPs (Rajaram et al. 1997). 
 
 
5. IGFBP-1 
 
IGFBP-1, formerly also known as PP12, was the first of the IGFBPs to be purified and to 
have its cDNA cloned (Brinkman et al. 1988a, Julkunen et al. 1988). It is an important 
IGFBP as regards regulation of IGF availability and actions in most human tissues. 
 
5.1 Gene and protein structure 
 
The human IGFBP-1 gene is a single copy gene, located in chromosome 7 (p12-p13) 
(Brinkman et al. 1988a, Alitalo et al. 1989). The gene spans 5.2 kb and is divided into 4 
exons (Brinkman et al. 1988b). The 25 kDa IGFBP-1 protein sequence contains 12 N-
terminal and 6 C-terminal cysteine residues, which are also found in other IGFBPs and 
other mammalian IGFBP-1 sequences. Optimal IGF binding requires both cysteine-rich 
regions (Brinkman et al. 1991). The IGFBP-1 mid-region acts as a specific target for 
protease activity as well as a hinge defining ligand-binding characteristics (Lee et al. 
1993). 
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5.2 Production sites 
 
The IGFBP-1 gene is primarily expressed in the liver (Brinkman et al. 1988a, Julkunen et 
al. 1988), but also in decidualized endometrium (Rutanen et al. 1985, Julkunen et al. 
1988), ovarian granulosa cells (Suikkari et al. 1989a) and kidney (Chin et al. 1992, 
Suikkari et al. 1992). Expression of IGFBP-1 is also found in human coronary 
arteriectomy specimens (Grant et al. 1996). 
 
5.3 Function 
 
Together with the other IGFBPs, IGFBP-1 is an important regulator of local bioactivity of 
the insulin-like growth factors in various tissues (Shimasaki et al. 1991). In contrast to 
IGFBP-3, IGFBP-1 is for the most part unbound in serum, and it regulates acute changes in 
serum IGFs (Rajaram et al. 1997). It is believed that IGF-I can leave the circulating 
reservoir only in its free form or when bound to IGFBP-1 or -2 (Juul et al. 2002). Two 
major roles for IGFBP-1 in normal physiology have been suggested: 1) as an endocrine 
factor, IGFBP-1 regulates the bioavailability of serum IGF-I, thereby modulating IGF-
mediated tissue metabolism; 2) as an autocrine/paracrine factor, IGBP-1 plays an important 
role in the female reproductive system, from ovulation and implantation to successful fetal 
outcome (Lee et al. 1997). 
 
5.4 Phosphorylation 
 
IGFBP-1 exists as five different phosphoisoforms. Phosphorylation of IGFBP-1 is reported to 
increase the affinity for ligands and thus influence the ability of IGFs to interact with their 
receptors (Jones et al. 1991, Westwood et al. 1997). Phosphorylated IGFBP-1 variants have 
been identified in amniotic fluid, serum and decidua (Koistinen et al. 1993a). The variant 
present in nonpregnant human serum is highly phosphorylated. However, the degree of 
phosphorylation in maternal plasma varies during pregnancy so that nonphosphorylated and 
three lesser phosphorylated variants have been observed (Koistinen et al. 1993b, Westwood et 
al. 1994) The affinity of the highly phosphorylated form of IGFBP-1 for IGF-I is significantly 
greater than that of IGFBP-3, the main carrier of IGF in blood (Westwood et al. 1997). It 
appears that normally, IGFBP-1 in the circulation inhibits IGF actions; however, changes in 
IGFBP-1 phosphorylation status may permit increased IGF bioavailability. 
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5.5 Regulation 
 
HepG2 cell cultures 
The human HepG2 hepatoma cell line has been used to study regulation of IGFBP-1 
production in vitro (Conover et al. 1990). Earlier studies have shown an inhibitory effect of 
insulin on the production of IGFPB-1 (Conover et al. 1990, Lee et al. 1993). The effects of 
IGF-I on IGFBP-1 production have been described as variable, ranging from inhibitory to no 
effect at all (Conover et al. 1990, Singh et al. 1990). IGF-II appears to have an inhibitory 
effect on IGFBP-1 (Lee et al. 1993). Glucocorticoids and cAMP stimulate IGFBP-1 
transcription (Conover et al. 1993). Epidermal growth factor (Angervo et al. 1992), tri-
iodothyronine (Angervo et al. 1993a) and the cytokines TNF-α, IL-1β and IL-6 (Samstein et 
al. 1996, Benbassat et al. 1999) increase the synthesis of IGFBP-1 in HepG2 cells (Table 1). 
 
 
Table 1. Summary of previous in vitro studies of IGFBP-1, IGFBP-3 and SHBG production in HepG2 cells. 
(For references, see text) 
 
 IGFBP-1 SHBG IGFBP-3 
Insulin ↓  ↓ ND 
IGF-I ↓ / −  ↓ ND 
IGF-II ↓ ND ND 
GH ND ND  ↑ 
    
estradiol ND  ↑ / − ND 
tamoxifen ND  ↑ / − ND 
testosterone ND ↑ / ↓ ND 
T3  ↑ ↑ / ↓ ND 
ND: not determined 
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Physiological conditions 
IGFBP-1 differs from other IGFBPs, as plasma concentrations show marked diurnal 
variation, first reported among pregnant women (Rutanen et al. 1984). In the nonpregnant 
state, plasma levels show a difference of over 10-fold between midnight and morning 
regardless of metabolic and hormonal status (Baxter et al. 1987). These changes are 
obviously associated with nutritional factors, with elevated values during fasting (Busby et 
al. 1988, Hall et al. 1988). 
 
The concentration of IGFBP-1 in human fetal serum is 10 times higher than in cord plasma 
of term infants. The levels continue to decline after birth until a steady state is reached at 
puberty (Hall et al. 1988). Serum IGFBP-l concentrations decline in adolescence (Argente 
et al. 1993) and remain low in adulthood. With advancing age, there may be a slight 
increase in serum IGFBP-l concentrations as the inverse correlation with insulin levels 
becomes less pronounced (Rutanen et al. 1993). 
 
IGFs and IGFBPs are produced locally by cells of the cardiovascular system, vascular 
smooth muscle cells and endothelial cells (Delafontaine 1995). They act as growth 
promoters for arterial cells and mediators in cardiovascular disease (Bayes-Genis et al. 
2000). 
 
Pathological conditions 
Insulin is the primary determinant of IGFBP-1 expression (Suikkari et al. 1988, Lee et al. 
1997). Studies in patients with type 1 diabetes have confirmed that insulin potently 
suppresses the hepatic output of IGFBP-1 (Brismar et al. 1994). IGF-I and IGF-II also 
have specific inhibitory effects on IGFBP-1 expression. Other factors stimulating IGFBP-1 
expression include thyroid hormones (Angervo et al. 1993b). Progesterone and other 
factors that enhance decidualization induce IGFBP-1 production in the endometrium (Gao 
et al. 1999). The relationships between IGFBP-1, type 2 diabetes and cardiovascular risk 
are reviewed in a separate chapter. 
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6. IGFBP-3 
 
6.1 Gene and protein structure 
 
The human IGFBP-3 gene is a single copy gene located on chromosome 7. The gene spans 
8.9 kilobases and the protein-coding region is divided into four exons while the fifth exon 
contains a 3'-untranslated region (Cubbage et al. 1990). There is close physical linkage 
between the IGBP-1 and IGBP-3 genes; they are isolated, but are arranged in a tail-to-tail 
fashion separated by 20 kb of DNA (Ehrenborg et al. 1992). 
 
Insulin-like growth factor binding protein-3 is a 40–45 kDa glycoprotein sharing the basic 
structure of other IGFBPs, with conserved amino- and carboxyl-terminal regions and a unique 
central region. IGFBP-3 is characterized by its ability to bind to another glycoprotein, the 85 
kDa acid-labile subunit (ALS), in the presence of either IGF-I or IGF-II to form a ternary 
complex of 150 kDa (Baxter et al. 1989). The protein-protein and protein-cell interactions of 
IGFBP-3 are complex and involve distinct domains of the protein. The structural integrity of 
the IGF-I binding site is disrupted significantly by deletion of either the central or carboxyl-
terminal region of IGFBP-3, but more specific mutations of the carboxyl-terminal region can 
reduce IGF-I binding. The IGF-I and ALS binding sites are functionally distinct (Firth et al. 
1998). 
 
6.2 Function 
 
IGFBP-3 is the major IGF carrier in human serum. It is synthesized in many tissues, mainly in 
the liver (Clemmons et al. 1991, Donaghy et al. 1995). Its serum levels are more than 10-fold 
higher than those of the other IGFBPs and over 80% of circulating IGF-I is bound to IGFBP-
3. IGFBP-3 circulates in a 150 kDa ternary complex together with IGF-I or IGF-II and ALS. 
This complex extends the half-life of IGF-I in serum to approximately 15 h, compared with 
20–30 min for the IGF-IGFBP-1 complex and 10–12 min for free IGF-I (Guler et al. 1989). 
Formation of the ternary complexes restricts the IGFs to the circulation as it prevents IGFs 
and IGFBP-3 from crossing the capillary barrier (Baxter 1994). 
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IGFBP-3 has been shown to have direct IGF-independent cellular effects, such as stimulation 
and inhibition of cell proliferation (Jones and Clemmons 1995), induction of apoptosis (Gill et 
al. 1997, Rajah et al. 1997) and nuclear translocation (Jaques et al. 1997). It is thought that 
cell-surface association is needed for many of these functions (Firth et al. 1999), but no 
specific receptor has been identified. However, high IGFBP-3 concentrations are associated 
with a decreased risk of cancer (Renehan et al. 2004). 
 
6.3 Regulation 
 
Specific proteases for IGFBP-3 have been described, including serine proteases, cathepsins 
and matrix metalloproteinases (Wetterau et al. 1999). Proteolysis results in the formation of 
fragments with 23- to 30-fold decreased affinity for IGFs, thus regulating the bioavailability 
of IGFs. 
 
Another mechanism of posttranslational modification of IGFBP-3 is glycosylation. The amino 
acid sequence of IGFBP-3 has three potential N-glycosylation sites in the central region (Firth 
et al. 1999). Human IGFBP-3 is usually found as two differently glycosylated forms of 40–45 
kDa (Tressel et al. 1991). The state of glycosylation has not been found to affect IGF- or 
ALS-binding in vitro (Conover 1991, Firth et al. 1999). While glycosylation does not appear 
to play a role in IGFBP-3 ligand binding, the level of glycosylation has the potential to 
modulate the cell-binding activity of IGFBP-3 (Firth et al. 1999). 
 
Human hepatoma cell cultures 
Serum IGFBP-3 levels are regulated by the GH/IGF-I system so that growth hormone 
stimulates IGF-I, which in turn directly increases IGFBP-3 secretion (Jørgensen et al. 1991). 
IGFBP-3 cDNA has been cloned from a human liver cDNA library (Wood et al. 1988, Spratt 
et al. 1990). However, isolated rat hepatocyte cultures do not release IGFBP-3, and only 
nonparenchymal rat liver cells have been shown to contain its mRNA (Takenaka et al. 1991, 
Villafuerte et al. 1994). Cultures of human liver hepatocytes, lipocytes and Kupfer cells have 
been demonstrated to contain both IGFBP-3 mRNA and the corresponding immunoreactive 
protein (Arany et al. 1994). The direct effect of insulin on IGFBP-3 production in vitro in 
hepatoma cells has not been studied previously. The effect of IGF-I on IGFBP-3 production 
has been tested with two hepatoma cell lines, PLC (Scharf et al. 1998) and SKHEP (Gucev et 
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al. 1997), as has the effect of IGF-II in PLC cells, but not with the HepG2 cell line, which is 
known to secrete many proteins of normal liver tissue (Knowles et al. 1980) (Table 1). 
 
Physiological conditions 
The serum concentrations of immunoreactive IGFBP-3 are low at birth, increase 3-fold in 
children towards the end of puberty, and then gradually decline from age 18 to 65 (Baxter 
1986, Koistinen et al. 1994). Circulating levels of IGFBP-3 fluctuate concomitantly with GH 
levels (Baxter 1986), and GH appears to play a dominant role in the regulation of IGFBP-3 in 
humans. Other factors influencing IGFBP-3 production are less well known. Unlike IGFBP-1, 
the circulating concentrations of IGFBP-3 show no diurnal variation (Clemmons et al. 1992). 
A single subcutaneous injection of human recombinant IGF-I has been shown to increase 
serum IGFBP-1 levels without affecting IGFBP-3 concentrations in normal subjects (Hizuka 
et al. 1993), whereas the administration of IGF-I to patients with non-insulin-dependent 
diabetes mellitus decreases serum IGFBP-3 levels (Lieberman 1992). 
 
Pathological conditions 
Disease states associated with altered serum IGFBP-3 concentrations include acromegaly 
(elevated levels), growth hormone deficiency and poorly controlled diabetes (subnormal 
levels) (Baxter 1986, Blum et al. 1990, Gargosky 1992). Slightly increased concentrations 
are seen in renal failure and third-trimester pregnancy (Blum et al. 1990, Gargosky 1992). 
Patients with liver cirrhosis have very low circulating IGFBP-3 levels that correlate with 
the degree of general liver dysfunction (Møller et al. 1995). This is not a result of increased 
IGFBP-3 proteolysis (Bang et al. 1994). 
 
 
7. SHBG  
 
SHBG is a multifunctional protein that acts in humans to regulate the response to steroids. It 
is the major binding protein for sex steroids in plasma, thereby determining the availability of 
free steroids to hormone-responsive tissues (Siiteri et al. 1982). It binds testosterone with high 
affinity and estrogens with lower affinity. Considerable variations in serum SHBG 
concentrations exist between individuals, depending on nutritional (Anderson et al. 1987, 
Kiddy et al. 1989), gender (Vermeulen et al. 1969), and hormonal status. SHBG also 
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functions as part of a steroid-signaling system that is independent of the classical intracellular 
steroid receptors (Kahn et al. 2002). 
 
7.1 Gene and protein structure 
 
The SHBG gene is located in chromosome region 17p13 and comprises at least 8 exons 
(Bérubé et al. 1990). The location is only 30 kb from the p53 tumor suppressor gene, in a 
region known to undergo allelic deletions and mutations in many tumor types (Cousin et al. 
2000). The question has been raised of whether genomic changes that alter the SHBG locus 
might lead to changes causing hormone-dependent cancers (Kahn et al. 2002). 
 
Human SHBG is a homodimeric glycoprotein, each monomer consisting of 373 amino acid 
residues (Walsh et al. 1986, Hammond and Bocchinfuso 1996) and containing a steroid-
binding site within an amino-terminal laminin G-like (LG) domain (Grishkovskaya et al. 
2000). Both androgens and estradiol compete for occupancy of this binding site, but appear to 
enter the site differently and are bound in opposite orientations (Grishkovskaya et al. 2000). 
Occupancy of the human SHBG steroid-binding site by estradiol is also accompanied by a 
specific conformation of amino acid residues on the surface of the protein that is not seen 
when the site is occupied by C19 steroids or the synthetic progestin levonorgestrel 
(Avvakumov et al. 2002). 
 
7.2 Function 
 
SHBG has two apparently disparate functions. It is the major regulator of free estrogens and 
androgens in plasma (Rosner et al. 1996) and it is an initiating component of a signaling 
system for estrogens and androgens at the cell membrane that functions via a G protein 
(Nakhla et al. 1999) and cAMP (Fortunati et al. 1999). 
 
SHBG functions as a modulator of androgen delivery to tissues. The unbound fraction of 
testosterone is bioavailable (Vermeulen et al. 1971). In the blood, changes in SHBG 
concentrations influence the distribution of sex hormones between the free and protein-bound 
fractions, of which only the free fraction is available for target cell uptake. In women, low 
concentrations of SHBG have been observed in conditions associated with excessive 
androgen action, such as hirsutism and acne (Anderson et al. 1974), and endometrial cancer 
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(Lukanova et al. 2004). In addition to natural steroids, SHBG binds several synthetic steroids, 
including the progestins used in contraceptives and hormonal replacement therapies (El 
Makhzangy et al. 1979). 
 
A specific, high-affinity SHBG receptor (R SHBG) has been found in cell membranes of the 
endometrium, prostate, placenta, breast, liver and epididymis. Unoccupied SHBG binds to the 
receptors on the cell membrane, followed by binding of steroid to the complex. Activation of 
R SHBG induces the synthesis of cAMP (Kahn et al.2002). 
 
7.3 Production sites 
 
Serum SHBG is mainly produced by the liver. Cultured hepatoma cells secrete SHBG and 
cDNAs coding for SHBG are found in human liver cDNA libraries (Khan et al. 1981, 
Hammond et al. 1987). It is becoming increasingly obvious that expression of the SHBG gene 
is far more complex than originally assumed and it is responsible for several related gene 
products in a wide range of tissues, including the breast, prostate, brain, placenta and 
endometrium (Hammond and Bocchinfuso 1996, Kahn et al. 2002). The biological 
significance of these gene products remains to be determined. Local production of SHBG in 
breast and prostate cells is probably independent of serum SHBG (Kahn et al. 2002). R SHBG 
signaling has been found to affect growth in human breast carcinoma and human prostate cell 
lines (Fortunati et al. 1996, Nakhla and Rosner 1996). It has been hypothesized that 
perturbations of SHBG expression in cancer cells might contribute to the malignant 
phenotype (Kahn et al. 2002). 
 
7.4 Regulation 
 
Human hepatoma cell cultures 
Inhibitory effects of insulin and IGF-I on the production of SHBG in HepG2 cells have been 
shown in previous studies (Plymate et al. 1988, Singh et al. 1990, Crave et al. 1995), even in 
the intracellular compartment (Loukovaara et al. 1995). The effect of IGF-II on SHBG 
production in liver or hepatoma cells is not known. Thyroid hormones increase the secretion 
of SHBG in vitro (Mercier-Bodard et al. 1989). Androgens have been found to increase 
SHBG production in most studies (Lee et al. 1987, Mercier-Bodard et al. 1987, Plymate et al. 
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1988, 1990). Estrogens and tamoxifen also increase SHBG production (Plymate et al. 1988, 
1990), but progestin has no effect (Mercier-Bodard et al. 1986, Lee et al. 1987) (Table 1). 
 
Physiological conditions 
Insulin is thought to be the most important regulator of SHBG metabolism in vivo (Nestler et 
al. 1993). Other regulators of SHBG production are sex steroids and thyroid hormones. 
 
In fetal plasma, the SHBG level is low but it rises in newborns (August et al. 1969). The 
concentration is stable thereafter, until it decreases during prepuberty in both sexes (Horst et 
al. 1977). After puberty mean values clearly differ between the sexes, with higher values in 
women than in men (Vermeulen et al. 1969). Serum SHBG concentrations rise with age 
(Maruyama et al. 1984). In men, approximately 44% of circulating testosterone is bound to 
SHBG. In women, a substantial proportion of estradiol, 37–88% depending on the phase of 
the menstrual cycle, circulates in complex with SHBG (Dunn et al. 1981). The menstrual 
cycle has not been found to affect SHBG levels (Pearlman et al. 1967). During pregnancy 
SHBG levels rise and reach a plateau at 25–30 weeks, being about ten-fold higher than in 
nonpregnant women (Pearlman et al. 1967). At menopause, the decrease in estrogen levels is 
not reflected in changes in SHBG levels in plasma (Longcope et al. 1987). Dietary factors can 
affect the SHBG level. Fasting increases it, probably by lowering insulin levels (Kiddy et al. 
1989). Levels of SHBG are also higher during a high carbohydrate diet than a high protein 
diet (Anderson et al. 1987). 
 
Pathological conditions 
Obesity is the most common condition affecting circulating SHBG levels, and in obese 
individuals SHBG concentrations are low in both sexes (Glass et al. 1977). This suppression 
appears to be a result of the effects of insulin on SHBG production (Peiris et al. 1989). 
Abnormally low serum SHBG levels are frequently found in women with polycystic ovarian 
syndrome (PCOS), and they contribute to hyperandrogenic symptoms such as hirsutism and 
acne (Anderson 1974). Serum SHBG levels are also reduced in patients with type 2 diabetes, 
and CHD (Lapidus et al. 1986, Lindstedt et al. 1991). 
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Hypothyreosis decreases and hyperthyreosis increases serum SHBG levels (Olivo et al. 
1970). These changes probably result from direct effects of thyroid hormones on hepatic 
SHBG production. In cases of male hypogonadism such as Klinefelter’s syndrome, SHBG 
levels are usually within the female range (DeMoor et al. 1969). In some conditions, such 
as Cushing’s syndrome and acromegaly, low SHBG levels are most likely caused by 
underlying disturbances in glucose metabolism, as the majority of these patients have 
impaired glucose tolerance or even diabetes (Daughaday 1995). 
 
In the majority of studies on SHBG levels and prostate cancer no differences have been found 
between cases and controls (Shaneyfelt et al. 2000), but in one prospective study with 
multivariate adjusted data men with the highest circulating SHBG levels were less likely to 
develop prostate cancer (Gann et al. 1996). Local SHBG production might be more important 
as regards cancer development (Kahn et al. 2002). 
 
 
8. REGULATION OF IGFBP-1 AND SHBG BY INSULIN AND IGFS 
 
Since portal hyperinsulinemia is a key feature of metabolic syndrome (Björntorp et al. 1988), 
the serum IGFBP-1 concentration might serve as a marker of hyperinsulinemia and insulin 
resistance by indicating insulin bioactivity in the portal vein (Yki-Järvinen et al. 1995). An 
easily measurable marker is needed, as the insulin clamp technique, the current gold standard 
for assaying insulin sensitivity (DeFronzo et al. 1979), is an invasive and technically 
demanding procedure not suited for large populations. The results of clinical studies indicate 
that IGFBP-1 concentrations correlate with cardiovascular risk factors (Harrela et al. 2000). 
Clinical studies have also shown an association between SHBG and hyperinsulinemic insulin 
resistance (Nestler et al. 1993). 
 
Earlier studies on HepG2 cells have shown an inhibitory effect of insulin on the production of 
both IGFBP-1 and SHBG (Plymate et al. 1988, Conover et al. 1990, Singh et al. 1990 Lee et 
al. 1993, Crave et al. 1995), while the effects of IGF-I have been variable, ranging from 
inhibitory to no effect at all (Singh et al. 1990, Crave et al. 1995, Loukovaara et al. 1995). 
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The effect of IGF-II is unknown. The relative potencies of insulin and insulin-like growth 
factors in regulation of the production of IGFBP-1 and SHBG by the liver is still unresolved. 
 
 
9. IGFBP-1 AND ESTROGENS 
 
9.1 Ovarian stimulation 
 
The ovary is a site of IGF, IGF-IR and IGFBP expression and action. IGFs stimulate ovarian 
cellular mitosis and steroidogenesis, and IGFBPs are inhibitory to these processes (Mason et 
al. 1992, Giudice et al. 1993). IGFBP-1 mRNA has been shown to be present in granulosa 
cells, notably in the dominant follicle (Koistinen et al. 1990, El-Roeiy et al. 1994). It is also 
increased in luteinizing follicles (Thierry van Dessel et al. 1996) and in follicles containing 
mature oocytes (Kawano et al. 1997). This suggests a role for IGFBP-1 in development of the 
dominant follicle and in corpus luteum regulation and thus a possible use as a marker of 
mature oocytes (Kawano et al. 1997, Fried et al. 2003). 
 
Both IGF-I and FSH stimulate estradiol and reduce IGFBP-1 production in cultured granulosa 
cells (Dor et al. 1992, Mason et al. 1993). In vivo, no significant variation in circulating 
IGFBP-1 concentrations has been observed during the normal menstrual cycle (Suikkari et al. 
1987, Pekonen et al. 1992, van Dessel et al. 1996). Ovarian stimulation is followed by rising 
estrogen and IGFBP-1 levels, both in follicular fluid and serum (Seppälä et al. 1984, 1988, 
Martikainen et al. 1992). However, whether the rise in serum levels of IGFBP-1 is caused by 
stimulation of production in the liver or ovary, or both, has not been determined. Normally, 
circulating IGFBP-1 is derived mainly from the liver, but in controlled ovarian 
hyperstimulation the contribution from hyperstimulated preovulatory follicles may be 
important (Martikainen et al. 1991, 1992, Pekonen et al. 1992). A recent finding of 
approximately ten-fold higher levels of IGFBP-1 in follicular fluid during superovulation 
treatment as compared with serum levels supports this idea (Fried et al. 2003). If also GH is 
given during superovulation treatment, serum IGFBP-1 values decrease significantly, 
compared with the situation in women receiving only gonadotropins, while IGF-I and insulin 
values remain unchanged (Tapanainen et al. 1991). 
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9.2. Hormone treatment 
 
Changes in serum IGF-I and IGFBP-1 levels are also found during hormone therapy (HT). In 
particular, oral estrogen therapy (ET) is associated with a decrease in serum levels of IGF-I 
and an increase in those of IGFBP-1 (Weissberger et al. 1991, Kelly et al. 1993, Campagnoli 
et al. 1995, Helle et al. 1996, Paassilta et al. 2000). During transdermal ET, unaffected IGF-I 
levels have been reported (Weissberger et al. 1991, Bellantoni et al. 1996, Paassilta et al. 
2000). IGF-I levels drop only when exceptionally high doses of transdermal estrogen have 
been administered (Friend et al. 1996). Levels of IGFBP-1 also remain unchanged during 
transdermal ET. The estrogen antagonist tamoxifen has similar effects on the IGF system as 
estrogen in vivo (Lønning et al. 1992, Friedl et al. 1993, Decensi et al. 1999). 
 
Oral ET exerts its effects on serum IGF-I via a hepatic first pass effect. IGF-I is part of the 
hypothalamic-pituitary-hepatic axis complex involving GH-releasing and GH-inhibiting 
hormones (Paassilta et al. 2000). Thus, changes in plasma levels of IGF-I could reflect an 
indirect effect of estrogen, the primary effect being extrahepatic. Animal studies have 
suggested that the primary target of estrogen action could be the pituitary, and that the IGF-I-
lowering effect of estrogen takes place indirectly (Krattenmacher et al. 1994). In addition, 
oral therapy with conjugated estrogen has been reported to increase GH levels in 
postmenopausal women (Bellantoni et al. 1996). During transdermal ET, however, estradiol 
is delivered directly into the peripheral circulation. Therefore, hepatic exposure to estradiol 
might be of importance in inducing the changes in the IGF system. It has been proposed that 
the effects of oral estrogen on the IGF system are mediated, in whole or in part, by down-
regulation of growth hormone signaling in hepatocytes (McCarty 2003). 
 
 
10. METABOLIC SYNDROME, DIABETES RISK AND MORTALITY 
 
Metabolic syndrome involves disturbances in glucose metabolism and insulin secretion, an 
overweight condition, abdominal fat distribution, dyslipidemia and hypertension. It has a 
close association with subsequent development of type 2 diabetes and cardiovascular disease 
(Reaven et al. 1988). The underlying abnormality is considered to be insulin resistance. The 
pathogenesis of metabolic syndrome is not clear, but dietary factors and physical activity 
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clearly interact in development of the syndrome, together with as yet unknown genetic factors 
(Liese et al. 1998). The diagnosis of metabolic syndrome requires multiple laboratory tests. 
As the syndrome is becoming increasingly common in the Western world, practical tools for 
mass screening for it should be helpful. 
 
Formerly, definitions of this syndrome have varied widely and the names metabolic syndrome 
and insulin resistance syndrome have both been used. The World Health Organization (WHO) 
and the National Cholesterol Education Program (NCEP) Expert Panel have both published 
recent definitions (Table 2) (Alberti et al. 1998, Balkau et al. 1999). 
 
Table 2: WHO and NCEP definitions of the metabolic syndrome in men 
 
 
WHO Definition     NCEP Definition  
  
Hyperinsulinemia (upper quartile of the nondiabetic 
population) or fasting plasma glucose ≥ 6.1 nmol/l 
  At least 3 of the following: 
AND  
At least 2 of the following   Fasting plasma glucose ≥ 6.1 nmol/l 
Abdominal obesity:   Abdominal obesity: 
  -Definition 1: Waist hip ratio >90 or BMI = 30   -Definition 1: waist girth > 102 cm 
-Definition 2: Waist girth > 94 cm -  Definition 2: Waist girth > 94 cm 
Dyslipidemia (serum triglycerides ≥1.7 mmol/l or HDL 
cholesterol <0.9 mmol/l)  
Blood pressure ≥ 140/90 mmHg or medication 
  Serum triglycerides ≥1.7 mmol/l  
  Serum HDL cholesterol <0.9 mmol/l  
  Blood pressure ≥ 130/85 mmHg or medication 
  
 
 
 
Recent studies have shown that even subjects with metabolic syndrome but without diabetes 
have 2–3 fold CVD mortality (Malik et al. 2004). Those with diabetes had a 2-fold increase 
even in overall mortality. Even one or two metabolic syndrome features confer an increased 
risk of CHD and CVD mortality (Malik et al. 2004). 
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11. IGFBP-1 AND SHBG IN METABOLIC SYNDROME AND DIABETES 
 
The relationship between androgen homeostasis, insulin sensitivity and cardiovascular risk in 
men is complex. Low levels of SHBG, and free or total testosterone in men have been 
associated with type 2 diabetes, visceral obesity, insulin resistance or hyperinsulinemia, 
dyslipidemia and metabolic syndrome (Haffner et al. 1996, Laaksonen et al. 2003). 
Testosterone and insulin concentrations are inversely associated in healthy men (Simon et al. 
1992). Testosterone may have a central role in the pathogenesis of metabolic syndrome or 
type 2 diabetes, as it increases skeletal muscle tissue and decreases abdominal obesity and 
nonesterified fatty acids, consequently improving insulin sensitivity (Marin et al. 1992). 
 
In contrast to total testosterone, calculated free testosterone levels have not been found to 
predict the development of metabolic syndrome or diabetes in previous studies (Stellato et al. 
2000, Laaksonen et al. 2004). Because the level of free testosterone is related to that of 
SHBG, it may be that SHBG is more important than testosterone itself as a risk marker or as a 
contributor to the development of metabolic syndrome or diabetes (Laaksonen et al. 2004). 
Weight loss and successful weight maintenance increase free and total testosterone and SHBG 
in men with general obesity or abdominal obesity and metabolic syndrome (Kaukua et al. 
2003, Niskanen et al. 2004). 
 
In relatively small trials androgen treatment has improved insulin sensitivity in middle-aged 
abdominally obese men (Marin et al. 1992, 1995), but the findings have not been consistent 
(Liu et al. 2003). The results of some studies suggest that exogenous administration of 
androgenic steroids to men or women results in insulin resistance (Cohen et al. 1987). In 
other studies administration of testosterone has improved insulin sensitivity, probably through 
improvements in body composition and reduction in circulating nonesterified fatty acids 
(Marin et al. 1992, Marin 1995). A window for optimal insulin sensitivity has been suggested, 
as both elevated and low testosterone concentrations can reduce body sensitivity to insulin 
(Björntorp 1991). The results of most studies suggest a less atherogenic lipid profile with 
increasing endogenous total testosterone (Barrett-Connor 1995). Testosterone could be an 
independent risk factor for cardiovascular diseases or its effects may be mediated via other 
risk factors such as insulin levels. 
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Portal hyperinsulinemia is a key feature of metabolic syndrome (Björntorp 1988). SHBG and 
IGFBP-1 have been suggested as potential indicators of metabolic syndrome and 
hyperinsulinemia-related cardiovascular risk (Nestler et al. 1993). An association between 
low SHBG levels and the development of type 2 diabetes has also been reported (Lindstedt et 
al. 1991, Birkeland et al. 1993, Haffner et al. 1993, 1996, Gyllenborg et al. 2001). 
 
In insulin clamp studies, the relative insulin-induced decline of IGFBP-1 serum 
concentrations is 18 times greater than that of SHBG (Ebeling et al. 1995). Therefore, 
IGFBP-1 might correlate better than SHBG with hyperinsulinemia and its related 
cardiovascular risk factors. Moreover, IGFBP-1 might be devoid of the effects of confounding 
factors, such as estrogens and testosterone. Estrogen increases SHBG concentrations whereas 
testosterone decreases both SHBG levels and insulin sensitivity (Björntorp et al. 1991). 
 
 
12. THE IGF SYSTEM IN PREGNANCY  
 
Both maternal and fetal IGFs and IGFBPs play important roles in fetal growth and 
development (D’Ercole 1992, Chard et al. 1994, Tazuke et al. 1996). IGFBP-1 is synthesized 
in large amounts by the secretory endometrium and decidua of early pregnancy. Fetal serum 
IGFBP-1 is produced mainly in the liver, but also in some other tissues, including the fetal 
pancreas (Hill et al. 1989). In fetal growth disorders changes in the IGF system can be found, 
IGF-I and IGFBP-1 concentrations being decreased in cord sera from small-for-gestational 
age (SGA) newborns and increased in large-for-gestational age (LGA) newborns (Verhaeghe 
et al. 1993, Giudice et al. 1995). Some investigators have also reported low IGF-II levels in 
small fetuses (Verhaeghe et al. 1993, Giudice et al. 1995), while others have shown no such 
association (Lassarre et al. 1991). Low IGFBP-3 and increased IGFBP-1 levels have also 
been found in cord blood of SGA infants (Giudice et al. 1995). 
 
Several changes occur in the IGF system during pregnancy. Maternal serum concentrations of 
IGF-I rise progressively throughout pregnancy (Wilson 1982, Hall et al. 1984, Wang et al. 
1991), and its levels are determined by the mean concentration of GH derived from the 
placenta.  Levels of IGFBP-1 and IGFBP-3 in maternal plasma also rise with gestational age 
(Drop et al. 1984, Langford 1995). Decidual tissues are the main source of IGFBP-1 in 
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maternal serum (Rutanen et al. 1985). As in the decidua (Koistinen et al. 1993b), the 
phosphorylation state of IGFBP-1 in maternal plasma is altered during pregnancy, as a 
nonphosphorylated and three less phosphorylated forms appear in the plasma (Westwood et 
al. 1994). Levels of IGFBP-1 are often elevated in preeclampsia (Iino et al. 1986), while 
those of IGFBP-3 remain unchanged (Varma et al. 1993). 
 
Maternal levels of circulating IGFBP-3 have been shown to be increased in the third trimester 
of pregnancy compared with nonpregnant values (Baxter et al. 1986). The presence of a 
specific protease acting on IGFBP-3 was first suspected in 1990 (Fielder et al. 1990). 
Proteolysis of IGFBP-3 has been demonstrated in a variety of conditions. It has been 
suggested that proteolytic activity increases in the order: acromegalic patients, normal 
subjects, GH-deficient patients and pregnant women (Lassarre et al. 1991). Proteolytic 
activity is also observed during severe illness (Davies et al. 1991) and after surgery 
(Davenport et al. 1992). Proteolysis of IGFBP-3 in maternal serum may provide a mechanism 
to increase IGF availability required for fetal and placental growth (Rutanen et al. 2000). 
 
 
13. THE IGF SYSTEM IN DELIVERY AND PREMATURE RUPTURE OF FETAL 
MEMBRANES 
 
The IGF system plays an important role in the onset of labor. In vitro, IGF-I decreases the 
release of placental prostaglandin F2 and thromboxane, both with vasoconstricting properties. 
This is one of the mechanisms by which IGF-I is believed to increase placental blood flow 
and maintain pregnancy (Siler-Khodr et al. 1993). Concordant with this, serum IGF-I levels 
are low during delivery in the third trimester, compared with pregnancies without regular 
uterine contractions (Wang et al. 1993). In term and preterm deliveries, the endocrinological 
changes have been found to be similar, i.e. the cascade leading to preterm birth represents a 
normal signal with inappropriate timing rather than an abnormal signal (Steer 1990). Serum 
levels of IGF-I are also similar during term and preterm parturition (Wang et al. 1993). 
 
Increased IGFBP-1 levels have been observed during labor as compared with samples from 
infants delivered by cesarean section before the onset of labor, in cord blood (Hills et al. 
1994) and maternal serum (Wang et al. 1995). Maternal IGFBP-1 levels have been reported to 
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be inversely related to those of insulin (Wang et al. 1995). The reason for IGFBP-1 
concentration changes during labor could be acute stress, regulated by insulin (Lee et al. 
1997). 
 
In spite of increasing knowledge of the etiology and associated changes behind PROM and 
subsequent preterm delivery, they remain important causes of perinatal mortality and 
morbidity. Preterm delivery is preceded by premature rupture of membranes (PROM) in 
about one-third of the cases (Arias et al. 1982). Levels of IGF or IGFBP in women with 
PROM and preterm delivery, before regular uterine contractions appear, have not been 
studied previously. Premature rupture of membranes invariably leads to preterm delivery 
sooner or later (Cox 1988) and is associated with chorioamnionitis in up to 70% of cases 
(Naeye 1980). The role of infection is gaining importance in the etiology of preterm birth. Up 
to 80% of women who deliver before 30 weeks of gestation have evidence of bacterial 
infection in the amniotic fluid and/or membranes, compared with only 30% at 37 weeks of 
gestation (Goldenberg et al. 2000). Infections have been found to change IGF-I and IGFBP-3 
levels in serum. The levels are low in generalized infection, as shown in children with 
perinatal human immunodeficiency virus infection and serious disease (de Martino 2000). 
Low IGFBP-3 levels have also been found in other severely ill patients (Davies 1991) and 
after surgery (Davenport 1992). 
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AIMS OF THE STUDY 
 
Circulating IGFBPs and SHBG are important regulators of human glucose and sex hormone 
metabolism, as well as female reproductive functions. This study was designed to address 
different aspects of regulation of IGFBP and SHBG production as well as the clinical 
situations associated with metabolic syndrome and preterm delivery. The specific aims were: 
 
1. To compare the effects of insulin and IGFs on IGFBP-1 and SHBG production in 
human hepatoma cells.  
2. To study IGFBP-1 responses to estradiol in human hepatoma cells using SHBG as a 
control, and thus to investigate the possible source of elevation of serum IGFBP-1 
levels caused by high estradiol values during hormone treatments.  
3. To study in vitro the effects of insulin, IGF-I, IGF-II, sex hormones and cortisol on 
IGFBP-3, the GH-regulated major modulator of IGF action in the circulation.  
4. To study and compare serum SHBG and IGFBP-1 levels as potential indicators of 
glucose intolerance, metabolic syndrome, diabetes, cardiovascular risk and CVD 
mortality in elderly men. 
5. To evaluate whether maternal circulating levels of IGF-I and IGFBP-3 are affected in 
PROM or preterm delivery. 
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MATERIALS AND METHODS  
 
 
1. IN VITRO STUDIES (I, II, III) 
 
1.1 Cell cultures  
 
Human hepatoma cells (HepG2 cells) were grown at 37 °C in 92% air/8% CO2, in 
Dulbecco's Modified Eagle's Medium without phenol red, supplemented (10%) with heat-
inactivated fetal calf serum, 2 mM L-glutamine, 1 mM nonessential amino acids, penicillin 
(100 U/mL) and streptomycin (100 µg/mL). The HepG2 cells were grown to 
subconfluence for three days. The subconfluent cell layers were washed twice with 
phosphate-buffered saline, after which the cells were cultivated for one day under serum-
free conditions. The medium was then replaced with fresh serum-free medium, and the 
cells were cultivated in the presence or absence of hormones for another two days for 
IGFBP-1, IGFBP-3 and SHBG protein measurements, or for six hours for RNA 
experiments. For protein assays each experiment was performed three times with six 
observations for each hormone concentration. At the end of the incubation, the media were 
removed and stored at -20 °C until assayed. Cell viability was determined by means of 
trypan blue uptake. The cells for cellular IGFBP-1, SHBG and DNA measurements (I) 
were washed with PBS, harvested mechanically in 1.5 mL PBS, and stored at -20 °C until 
being homogenized and assayed. Homogenization was carried out by sonication. The cells 
for RNA extraction (II, III) were used immediately. 
 
1.2 Assays 
 
IGFBP-1 measurement (I, II, IV) 
Concentrations of IGFBP-1 in homogenized HepG2 cells (I), culture media (I, II) and 
serum (IV) were determined using a specific immunofluorometric assay (IFMA) 
performed essentially as described previously (Koistinen et al. 1996), using two 
monoclonal antibodies, F34-15C9 and F36-9G3. Briefly, the first antibody was bound to 
polystyrene microtiter wells and the second antibody was labeled with europium chelate. 
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The sensitivity of the assay was 0.1 µg/L, intra-assay variation was 3–11%, interassay 
variation was 4–10% and the linear measuring range was 0.1–100 µg/L. 
 
IGFBP-3 measurement (III, V) 
Concentrations of IGFBP-3 in culture media (III) and maternal serum (V) were determined 
by a highly specific and sensitive immunofluorometric assay described previously 
(Koistinen et al. 1994). Briefly, monoclonal antibodies (Mabs) were generated against 
recombinant IGFBP-3E.Coli. The assay employed Mab F42-1B6 as the solid phase 
antibody and Mab F41-5C11 as europium-labeled tracer. The intra-assay variation was 
3.6–6.2% and the interassay variation 5.4–11%. There are no cross-reactions with other 
human IGFBPs or IGFs in this assay (Koistinen et al. 1994). 
 
SHBG measurement (I, II, IV) 
A commercial immunofluorometric assay (Delfia SHBG Assay, Wallac Oy, Turku, 
Finland) was used, based on the direct sandwich technique in which polyclonal rabbit anti-
SHBG antibodies and monoclonal mouse anti-SHBG antibodies are employed. The 
sensitivity of the assay was 0.01 µg/dL (0.5 nmol/L), intra- and interassay coefficients 
were 7.8% and 9.1% respectively, and the measuring range was 0.01–5 µg/dL (0.5–200 
nmol/L). 
 
IGF-I measurement (V) 
Serum concentrations of IGF-I were measured by commercial enzyme-linked immunosorbent 
assay, following the instructions of the manufacturer (Diagnostic Systems Laboratories, 
Webster, TX, USA). The intra- and interassay coefficients of variation were 4.5–7.1% and 
4.8–8.8%, respectively. 
 
Isolation of total RNA and Northern blotting analysis (I, III) 
Total hepatocyte RNA was extracted by treating the cells with 4 M guanidinium 
isothiocyanate, followed by acid-guanidinium-thiocyanate-phenol-chloroform extraction 
(Chomczynski et al. 1987). RNA was quantified by measuring ultraviolet absorbance at 260 
nm. 
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Total RNA (20 µg) was subjected to electrophoresis and transferred to nylon membrane. For 
IGFBP-1, the entire 1.5-kb-long human IGFBP-1 cDNA (Villafuerte et al. 1994) was used as 
a probe. The 679-bp-long IGFBP-3 cDNA was cloned from decidua and the 402-bp-long 
SHBG cDNA from HepG2 cells by RT-PCR. Labeling of EcoRI fragments was performed by 
means of the rediprime DNA-labeling system. The filter was hybridized overnight at 68 °C 
using Express Hyb hybridization solution and 32P-labeled IGFBP-1, IGFBP-3 or SHBG 
cDNA. For autoradiography, the filter was exposed to Hyperfilm-MP film for 12 h. 
Ribosomal RNA was used to quantify the amount and to control the quality of loaded RNA. 
The amounts of IGFBP-3 and ribosomal RNA were estimated from autoradiographs and gels, 
respectively, using a UV transilluminator with and without a UV-to-white converter, 
respectively, and the GeneTools program. 
 
DNA measurement (II) 
The amount of cellular DNA was determined by means of a slight modification of the 
procedure described by Sorger and Germinario (1983), based on measurement of the 
relative fluorescence of a DNA-4',6'-diamidino-2-phenylindole complex. 
 
1.3 Statistical methods 
 
The results were expressed as a percentage of the control value in each case, and given as the 
mean ± SEM of six culture wells for each dose and hormone for protein analysis. The 
differences in levels between cultures with and without the hormones were evaluated by 
factorial analysis of variance (I, III) or the Mann–Whitney U test (II). A value of p < 0.05 was 
considered statistically significant. 
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2. CLINICAL STUDIES (IV, V) 
 
2.1 Study Subjects  
 
Study IV 
The study subjects came from the Seven Countries Study, initiated as a cardiovascular risk survey 
among 16 cohorts of men in seven countries in 1959 (Keys et al. 1966). The original cohorts of the 
Finnish part of the study consisted of men born between 1900 and 1919 in two geographically 
defined rural areas in eastern (n = 823) and south-western (n = 888) Finland (Nissinen et al. 1993). 
Of the original cohort, 524 were alive on the 1st of January 1989, 413 participated in the 30-year 
examination, and 335 men formed the study group for the present analysis. Reasons for non-
participation of these 70- to 89-year-old men included long distance travel, poor health, inadequate 
fasting and unwillingness to participate. Prevalent diseases in the study population are given in 
Table 3. All the subjects had given informed consent, and the Ethics Committee of the National 
Public Health Institute approved the study design. 
 
 
 
Table 3. Prevalent diseases in study population (IV) 
 
n % 
  
Metabolic syndrome 94 28 
Impaired fasting glucose (IFG) 20 6 
Impaired glucose tolerance (IGT) 37 11 
IFG and IGT 17 5 
Diabetes 109 32 
Cardiovascular disease (CVD) 184 54 
 
 
Study V 
 
Thirty-two women were referred to Helsinki University Central Hospital because of premature 
rupture of the membranes (PROM), defined as an identifiable leakage of amniotic fluid before the 
37th gestational week. General characteristics of the study population are 
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given in Table 4. Women with regular uterine contractions were excluded. All the women 
except one received a 3-day course of prophylactic cefuroxime. Betamethasone, 12 mg, was 
given twice, with a 12-hour interval, at < 32 gestational weeks. Twenty-seven healthy 
pregnant women from antenatal clinics served as gestational age-matched controls. The study 
was carried out with the approval of the Institutional Review Board of the Department of 
Obstetrics and Gynecology, Helsinki University Central Hospital, and all the study subjects 
gave informed consent. 
 
 
Table 4. Characteristics of the control subjects and PROM patients (V)  
 
 
Control subjects  
(n = 27)  
PROM patients  
(n = 32)  
Age (years) (mean ± SEM) 30 ± 1 32 ± 1 
Primiparae (%) 63 37 
Gestational age at PROM (weeks) (mean ± SEM)  29.1 ± 0.6 
Gestational age at delivery (days) (mean ± SEM) 39.9 ± 0.1 31.9 ± 0.4 
Interval from PROM to delivery (days) (mean ± SEM)  19 ± 3 
First serum sample (weeks) (mean ± SEM) 29.9 ± 0.4 30.7 ± 0.4 
Cesarean section (%) 26 31 
Birth weight of the newborn (g) (mean ± SEM) 3657 ± 97 1846 ± 85 
Apgar scores < 7 at 1 min 0 28 
Use of corticosteroids (%) 0 84 
Use of antibiotics (%) 0 97 
 
 
2.2 Study protocols and laboratory analyses  
 
Study IV 
In Study IV, the examinations involved questionnaires, clinical investigations, physical 
performance measurements and laboratory investigations (Nissinen et al. 1993). Briefly, body 
weight was measured in light clothing to the nearest 100 g. Two measurements of blood 
pressure were performed by a trained nurse, on the right arms of men in a sitting position after 
five minutes rest. The mean of two measurements was used. 
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Glucose tolerance was tested using a 75 g oral glucose load as described by Stengård et al. 
(1993). The participants were asked to fast for at least 12 hours and the tests were carried out 
between 08.00 and 12.00 a.m. Blood glucose was measured in venous plasma using the 
glucose dehydrogenase method. Insulin analyses after fasting and 2 hours after the glucose 
load were performed using Pharmacia Diagnostica Phadeseph Insulin RIA kits. 
 
Total and high-density lipoprotein (HDL) cholesterol concentrations were analyzed in fresh 
sera by an enzymatic method using an Olli C 3000 photometer (Kone Ltd., Espoo, Finland). 
Levels of HDL-cholesterol were measured after precipitation of very low-density lipoprotein 
(VLDL) and low-density lipoprotein (LDL) cholesterol by the dextran-magnesium chloride 
method (Kostner 1976), and serum triglycerides were assayed after enzymatic hydrolyzation 
and determination of the liberated glycerol by colorimetry, with commercial reagents, using a 
KONE C automatic discrete analyzer. 
 
Study V  
Serum C-reactive protein (CRP) concentrations were measured by immunoturbidimetry 
(Harmoinen et al. 1981). Subclinical intrauterine infection was defined as a serum CRP 
concentration exceeding 12 mg/L (Kurki et al. 1990). 
 
2.3 Definitions of glucose tolerance and metabolic syndrome (IV) 
 
Glucose intolerance included both impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT). Diabetes, IFG and IGT were all defined according to the 1999 WHO 
definition (Alberti et al. 1998). In IFG, the venous plasma fasting glucose level was 5.6–6.1 
mmol/L and the two-hour post-glucose load was < 7.8 mmol/L. In IGT, the venous plasma 
fasting glucose level was under 6.1 mmol/L and the two-hour post-glucose load was 7.8–11.0 
mmol/L. In diabetes, the venous plasma fasting glucose level was ≥ 7.0 mmol/L and/or the 
two-hour post-glucose load was ≥ 11.1 mmol/L, or clinical diagnosis of diabetes was assessed 
on the basis of dietary, oral, or insulin treatment. 
 
Metabolic syndrome was defined according to the European Group for the Study of Insulin 
Resistance (Balkau et al. 1999). Hypertension was defined according to the definition agreed 
by the International Society of Hypertension, and the Sixth Joint National Committee 
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recommendations (Joint National Committee on prevention, detection and treatment of high 
blood pressure 1997). Thus, metabolic syndrome was defined as hyperinsulinemia, fasting 
hyperglycemia or diabetes (fasting serum glucose > 6.1 mmol/L) and at least two of the 
following: obesity (BMI ≥ 30 kg/m2), dyslipidemia (serum triglycerides ≥ 1.7 mmol/L and/or 
serum HDL cholesterol < 0.9 mmol/L), or hypertension (blood pressure ≥ 140/90 or use of 
blood pressure medication). Hyperinsulinemia was estimated on the basis of fasting insulin 
levels in the uppermost quartile of the nondiabetic population. 
 
2.4 Mortality data (IV) 
 
Mortality data were systemically collected from the Finnish Death Register. Death certificates 
and hospital records were collected for all the men who died between 1989 and 1997. A 
single reviewer recorded the cause of death in order to minimize variability. In 1997, the vital 
status of all subjects was ascertained through the Finnish Population Registry. In addition, for 
the study population, all hospital discharge diagnoses, with the ninth revision of the 
International Classification of Disease (IDC-9) (WHO 1977) codes 410–414, 426–438 and 
440–448 were identified from the National Hospital Discharge Register, and hospital records 
were collected and reviewed. The person coding the causes of death was blind to the risk 
factor status of the subject. Where multiple causes of death were recorded, priority was given 
to accidents, advance-stage cancer, coronary heart disease and stroke. Total, cardiovascular 
and CHD mortality were used as outcome parameters. 
 
2.5 Statistical methods 
 
Study IV 
Statistical analyses were performed using SPSS for Windows version 11.0. Pearson’s 
correlation coefficients were calculated for IGFBP-l, SHBG, testosterone and TSH levels, 
plus a number of cardiovascular risk factors and components of metabolic syndrome. Age- 
and BMI-adjusted mean values of IGFBP-1 and SHBG levels in metabolic syndrome, glucose 
intolerance and diabetes were estimated using general linear models. Relative risks (with 95% 
confidence intervals) of death from all causes, cardiovascular causes and coronary heart 
disease were estimated using Cox regression analyses. 
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Study V 
Differences between mean values were compared by analysis of variance and paired-samples 
t tests. Spearman’s correlation coefficients were calculated to examine bivariate relationships. 
A value of p < 0.05 was considered statistically significant. The results were presented as 
mean ± SEM. 
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RESULTS 
 
1. IN VITRO STUDIES 
 
1.1 Insulin and IGFs in the production of IGFBP-1 and SHBG (I)  
 
Over 90% of the cells were viable at the end of the experiments, and no difference in viability 
between control and experimental wells was found. At 6 h no changes were observed in 
IGFBP-1 or SHBG production. 
 
At a 30 nM concentration, insulin attenuated both IGFBP-1 and SHBG production by about 
35% from the control value at 48 h. At a 30 nM concentration, IGF-I inhibited IGFBP-1 and 
SHBG production by 20 and 24 percent, respectively. At a 30 nM concentration, IGF-II 
inhibited IGFBP-1 production by 32%, but for SHBG the decrease caused by IGF-II was only 
11%. (Table 5) 
 
 
Table 5. Regulation of IGFBP-1 and SHBG production by insulin, IGFs and estradiol (I, II) 
 
 IGFBP-1 SHBG 
   
Insulin ↓  ↓  
IGF-I ↓  ↓  
IGF-II ↓  ↓  
estradiol ns ↑ 
ns: no significant changes 
 
 
At a 30 nM concentration, IGF-I caused a 40% decrease in IGFBP-1 RNA levels, whereas 
insulin and IGF-II reduced them by 52%. The changes in SHBG RNA levels brought about by 
all hormones were smaller than those in IGFBP-1 RNA levels, 10–25 percent, and only the 
IGF-I-induced change was statistically significant  
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1.2 Estradiol in the production of IGFBP-1 and SHBG (II) 
 
The release of IGFBP-1 from HepG2 cells was 209.6 ± 3.5 (SEM) ng/µg DNA during the 
48-h experiment, showing no significant increase in the presence of estradiol (E2). 
Likewise, the intracellular IGFBP-1 concentration showed no significant change (14.6 ± 
0.2 and 15.7 ± 0.5 ng/µg DNA) in the presence of E2 at concentrations of 10 nmol/L to 2.5 
µmol/L (Table 5). 
 
Unlike the absence of IGFBP-1 responses to E2, a positive SHBG response to E2 was 
observed in HepG2 cells. At an E2 concentration of 0.5 µmol/L, the intracellular SHBG 
concentration increased from 9.8 ± 0.2 to 17.3 ± 0.5 pg/µg DNA (p < 0.0001), and at 2.5 
µmol E2/L it increased from 9.8 ± 0.2 to 19.4 ± 0.5 pg/µg DNA (p < 0.0001). However, no 
increased release of SHBG into culture medium was found (Table 5). 
 
The amount of DNA was similar in all wells, including the controls. The variation was 
between 27.58 and 32.90 µg/well in all groups. Cell growth was thus not affected by the 
amounts of E2 added. 
 
1.3 Regulation of IGFBP-3 by various hormones (III) 
 
Insulin stimulated IGFBP-3 release from HepG2 cells at concentrations of 1 nmol/L and 
higher. This increase was 2-fold at an insulin concentration of 30 nmol/L. Like insulin, IGF-I 
and IGF-II also enhanced IGFBP-3 secretion. The maximal increases (2-fold for IGF-I and 
2.5-fold for IGF-II) were observed with IGF concentrations of 30 nmol/L. (Table 6) The 
results concerning intracellular concentrations were similar. Total RNA was increased 1.7- to 
2-fold. 
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Table 6. Regulation of IGFBP-3 production by various hormones (study III) 
 
 IGFBP3 
Insulin  ↑ 
IGF-I  ↑ 
IGF-II  ↑ 
estradiol ns 
tamoxifen ns 
testosterone ns 
cortisol ↓  
ns: no significant changes 
 
Estradiol increased IGFBP-3 release at a supraphysiological concentration of 2.5 µmol/L, but 
not at lower concentrations of 10–500 nmol/L. Testosterone and tamoxifen had no effect on 
IGFBP-3 production at concentrations up to 2.5 µmol/L. Cortisol inhibited IGFBP-3 secretion 
at physiological concentrations. None of the effectors altered the total protein concentrations 
in the experimental wells. At the end of the experiment, cell viability was over 90 percent in 
test and control wells. 
 
 
2. CLINICAL STUDIES  
 
2.1 IGFBP-1 and SHBG in metabolic syndrome and cardiovascular risk (IV)  
 
In age-adjusted analysis, men with metabolic syndrome, glucose intolerance or diabetes had 
significantly lower mean values of SHBG concentrations compared with the rest of the men. 
The association between low SHBG levels and glucose intolerance and diabetes also 
remained significant after adjusting for BMI. For IGFBP-1 there was a significant inverse 
association with metabolic syndrome and glucose intolerance in age-adjusted analysis, but 
neither of the associations remained significant after adjusting for BMI. 
 
Fasting serum SHBG and IGFBP-1 concentrations showed several correlations with various 
cardiovascular risk factors in Pearson correlation analyses (Table 7). Levels of SHBG showed 
more frequent and stronger inverse correlations than IGFBP-1. Concentrations of SHBG 
correlated with fasting and two-hour glucose levels in the oral glucose tolerance tests, 
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whereas IGFBP-1 levels showed no correlation. Concentrations of both SHBG and IGFBP-1 
correlated with fasting and two-hour insulin levels in OGTTs. 
 
 
Table 7. Pearson correlation coefficients for CVD risk factors and studied factors 
 
  SHBG IGFBP-1 testosterone TSH 
Age -0.027  0.120 * -0.110 * -0.108 * 
BMI -0.228 ** -0.258 ** -0.258 **  0.015 
Total cholesterol  0.017  0.036  0.055  0.015 
HDL cholesterol  0.328 **  0.132 *  0.266 ** -0.103 
Triglycerides -0.318 ** -0.140 * -0.226 **  0.120 * 
Fasting glucose -0.266 ** -0.011 -0.224 ** -0.024 
2 h post-OGTT glucose -0.211 ** -0.106 -0.114  0.063 
Fasting insulin -0.383 ** -0.287 ** -0.275 **  0.148 * 
2 h post-OGTT insulin -0.295 ** -0.217 ** -0.190 **  0.157 * 
Systolic blood pressure -0.127 *  0.058 -0.008  0.034 
Diastolic blood pressure -0.101  0.019  0.009  0.027 
BMI: body mass index, OGTT:oral glucose tolerance test, CVD: cardiovascular disease 
**P<0.01 *P<0.05 
 
 
In Cox regression analysis, the lowest quartile of SHBG concentrations was related to an 
increased risk of cardiovascular and CHD mortality, whereas the lowest quartile of IGFBP-1 
levels was not related to an excess risk of either cardiovascular or CHD mortality. The highest 
quartile values of SHBG and IGFBP-1 showed no correlations with increased mortality. 
 
Testosterone concentrations showed correlations with cardiovascular risk factors similar to 
those of SHBG, but they did not correlate with systolic blood pressure. Plasma testosterone 
levels had a strong inverse association with glucose intolerance, metabolic syndrome and 
diabetes. 
 
The concentrations of thyroid hormones showed correlations with cardiovascular risk factors. 
Levels of TSH had no association with glucose intolerance or diabetes, but were associated 
with metabolic syndrome. 
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2.2 IGFBP-3 and IGF-I in PROM and preterm delivery (V) 
 
In the women with PROM, serum IGF-I and IGFBP-3 levels were not statistically different 
from those in the control subjects. Seventeen women with PROM showed elevated CRP 
levels (35 ± 6 [SEM] mg/L). In this group, the levels of serum IGF-I and IGFBP-3 did not 
differ from those in the control subjects, or in the 15 PROM women with normal CRP levels. 
Serial serum samples before delivery were obtained from 22 women with PROM. No 
consistent changes in IGF-I or IGFBP-3 concentrations were seen during the follow-up period 
of 9 ± 2 days. The last antepartum levels of IGF-I and IGFBP-3 correlated positively with the 
birth weight of the newborns in the PROM group (r = 0.417, p = 0.018 for IGF-I; r = 0.483, p 
= 0.005 for IGFBP-3) but not in the control group (r = 0.069, p = 0.733 for IGF-I; r = -0.223, 
p = 0.264 for IGFBP-3). 
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DISCUSSION 
 
 
1. IN VITRO STUDIES 
 
1.1 Cell cultures 
 
Culture of HepG2 cells is widely used as an experimental model for studies on hepatic IGFBP 
and SHBG production. HepG2 cells are highly differentiated human hepatoblastoma cells, 
which exhibit most of the characteristics of normal hepatocytes (Knowles et al. 1980). They 
are easier to obtain and culture than normal hepatocytes and grow in a more uniform manner. 
Naturally, the results of cell culture studies have limitations and the results should be viewed 
together with those from studies carried out in vivo. Whether normal liver cells respond to 
exogenous stimuli in the same way as HepG2 cells is not certain. Culture conditions might 
affect the results. As HepG2 cells are often grown on in a laboratory for a long time, 
subclones with characteristics different from those in the original cell line might occur. This 
can in some cases explain different results from different laboratories. The cells used in this 
study were obtained directly from the American type culture collection and were divided as 
few times as possible. 
 
1.2 Regulation of IGFBP-1 and SHBG by insulin and IGFs 
 
The results of insulin infusion studies have previously shown that insulin regulates IGFBP-1 
levels (Suikkari et al. 1988, 1989b), with a nonlinear inverse correlation between portal vein 
insulin concentrations and serum IGFBP-1 levels (Conover et al. 1992). As IGFBP-1 values 
are downregulated 18-fold more than SHBG levels in insulin clamp studies (Ebeling et al. 
1995), the initial hypothesis in this study was that the effect of insulin on hepatic IGFBP-1 
production might be greater than on SHBG production. However, no such difference was 
observed in the present in vitro study using hepatoma cells, as the decrease in production was 
found to be similar for both proteins. 
 
Insulin-like growth factor-I was found to decrease SHBG and IGFBP-1 production in HepG2 
cells to a lesser extent than insulin. The result is in concordance with that in a previous study 
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(Lee et al. 1993) in which reduction of IGFBP-1 production by IGF-I was observed. 
However, this has not been observed in all studies (Singh et al. 1990). The changes in SHBG 
concentrations were similar to those in previous investigations on HepG2 cells (Plymate et al. 
1988, Crave et al. 1995). Like insulin, IGF-I downregulated IGFBP-1 and SHBG in the same 
manner. In clinical studies on patients treated with either IGF-I or growth hormone, which 
increases IGF-I levels, an inverse correlation between plasma insulin and SHBG levels has 
been found, but no correlation between IGF-I and SHBG levels (Gafny et al. 1994). Likewise, 
in postmenopausal breast cancer patients, multivariate analysis has revealed that plasma 
SHBG concentrations correlate inversely with those of insulin, but not with those of IGF-I 
(Lønning et al. 1995). Serum IGFBP-1 and IGF-I levels have also been shown to correlate 
inversely (Hall et al. 1988, Wang et al. 1989, Lønning et al. 1995). 
 
Information on the effects of IGF-II on IGFBP-1 and SHBG synthesis is scarce. In the present 
study, IGF-II, like insulin and IGF- I, decreased production of both IGFBP-1 and SHBG. This 
effect was, however, smaller for SHBG than for IGFBP-1. The biological significance of this 
finding remains unresolved. 
 
The reduced IGFBP-1 release from HepG2 cells was probably a result of reduced synthesis, 
because IGF-I, IGF-II and insulin all downregulated IGFBP-1 RNA levels. This confirms the 
results of other studies (Powell et al. 1991, Lee et al. 1993). SHBG RNA was significantly 
reduced by IGF-I only. Reduction of SHBG mRNA by insulin has been shown in a previous 
study in which the incubation time was much longer than in this study (Loukovaara et al. 
1995). 
 
On the basis of the present in vitro data, it is concluded that insulin, IGF-I and IGF-II 
decrease both IGFBP-1 and SHBG protein production with similar maximal responses. The 
findings suggest that both IGFBP-1 and SHBG concentrations could act as highly sensitive 
indicators of insulin bioactivity, and thus be possible markers of abnormal glucose tolerance 
and metabolic syndrome. This hypothesis was tested in the clinical study (IV). 
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1.3 Regulation of IGFBP-1 and SHBG by estrogen 
 
Insulin is the major regulator of IGFBP-1 and SHBG secretion, as has been shown both in 
vivo and in vitro in many studies (Conover et al. 1990, Singh et al. 1990, Mercier-Bodard et 
al. 1991, Powell et al. 1991, Plymate et al. 1988). The thyroid hormones thyroxine and tri-
iodothyronine (Mercier-Bodard et al. 1989, Angervo et al. 1993a, 1993b), as well as the IGFs 
(Plymate et al. 1988, 1990, Lee et al. 1993) have been shown to regulate the two binding 
proteins in a similar fashion. However, there are clinical situations in which the changes in 
IGFBP-1 levels cannot be explained by changes in the concentrations of insulin or thyroid 
hormones. For instance, controlled ovarian hyperstimulation is accompanied by rising serum 
IGFBP-1 levels in the follicular phase, correlating with rising E2 levels, both in serum and in 
follicular fluid (Seppälä et al. 1984, 1988, Martikainen et al. 1992). The most likely sources 
of this IGFBP-1 are the liver and/or the ovary, because the third potential source, the 
endometrium, does not produce IGFBP-1 during the estrogen-dominated proliferative phase 
of the cycle (Koistinen et al. 1993). 
 
This study addressed the issue of whether the high serum IGFBP-1 concentrations 
observed during ovarian stimulation are of hepatic or nonhepatic origin, possibly resulting 
from stimulation of secretion from ovarian cells. In normal conditions, most of the 
circulating IGFBP-1 appears to be of hepatic origin. Thus it is logical to assume that the 
changes caused by estrogens would reflect the effects of estrogen on hepatic IGFBP-1 
production. However, during ovarian stimulation, IGFBP-1 production by ovarian 
granulosa cells is greatly increased and this might be the reason for the observed high 
IGFBP-1 concentrations. 
 
Serum IGFBP-1 and SHBG concentrations correlate with each other in many situations 
(Lønning et al. 1995), and SHBG has been found to be responsive to estrogens in vitro 
(Loukovaara et al. 1995) and in vivo (Odlind et al. 1982). The effect of estrogens is likely to 
be indirect, as there is no estrogen-responsive element in the SHBG gene (Hammond et al. 
1987). The data on transcriptional regulation is controversial (Mercier-Bodard et al. 1991, 
Crave et al. 1995, Loukovaara et al. 1995). In this study, increased intracellular SHBG 
concentrations in response to estradiol showed that the cells had retained their responsiveness 
under the culture conditions employed. Therefore, the absence of changes in IGFBP-1 
concentrations indicates that estradiol does not affect IGFBP-1 synthesis in these hepatoma 
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cells, as also confirmed in other studies (Mercier-Bodard et al. 1991). However, it is possible 
that some characteristics of HepG2 subclones may differ. 
 
The present results indicate that estradiol has little effect on hepatic IGFBP-1 secretion 
provided that normal liver cells respond to exogenous stimuli in the same way as HepG2 
cells. Given that the ovarian compartment contributes to the circulating IGFBP-1 pool 
(Seppälä et al. 1988, Martikainen et al. 1992), the results of the present study support the 
clinical hypothesis that the major source contributing to the circulating IGFBP-1 pool, the 
liver, does not appear to contribute significantly to the elevated IGFBP-1 levels observed 
in response to the rising estrogen levels during controlled ovarian hyperstimulation. 
 
1.4 Regulation of IGFBP-3 by insulin, IGFs, sex hormones and cortisol 
 
In the present study, insulin stimulated IGFBP-3 secretion from HepG2 cells even at 
concentrations that correspond to postprandial insulin levels in portal blood. The rapid effect 
suggests that insulin may regulate hepatic IGFBP-3 production under physiological 
conditions. Furthermore, the results may partly explain why IGFBP-3 levels are low in 
diabetic patients before insulin treatment is started (Bereket et al. 1995). The high sensitivity 
of HepG2 cells to insulin suggests that insulin effects are likely to be mediated directly 
through its own receptors, or via stimulation of IGF-I production. IGF-I and IGF-II also 
enhanced IGFBP-3 production from HepG2 cells. These results in liver carcinoma cells are in 
accordance with clinical observations that show that administration of IGF-I to patients with 
non-insulin-dependent diabetes mellitus increases serum IGFBP-3 levels (Lieberman 1992). 
Our results are also in accord with those of previous in vitro studies carried out with different 
types of hepatoma cells (Gucev et al. 1997, Scharf et al. 1998). 
 
The release of IGFBP-3 was not influenced by sex steroid hormones at physiological 
concentrations. This is in keeping with the results of clinical studies showing no fluctuation of 
IGFBP-3 levels during the menstrual cycle (Thierry van Dessel et al. 1996) and the fact that 
there is no gender difference in circulating IGFBP-3 concentrations after puberty (Juul et al. 
1995). High supraphysiological estradiol concentrations resulted in a slightly greater release 
of IGFBP-3, but this effect was small compared with SHBG concentrations in the same  
experiments. There is some discrepancy between the results of in vivo studies and the present 
in vitro study regarding the effects of glucocorticoids on IGFBP-3 levels. In vivo, 
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dexamethasone increases IGFBP-3 serum concentrations in healthy males (Miell et al. 1993), 
whereas we found a decrease in vitro. The limitations of cell culture studies could account for 
this, but it is also possible that in vivo confounding factors can affect the results. 
 
It is concluded that insulin and both IGFs stimulate IGFBP-3 production by cultured human 
hepatoma cells. In contrast, sex steroids and tamoxifen have no effect on IGFBP-3 secretion, 
whereas cortisol inhibits it. 
 
 
2. CLINICAL STUDIES 
 
2.1 Study populations 
 
In study IV the study population consisted of elderly men aged 70–89. As in all studies on 
elderly people, survivor bias may influence the findings, as the subjects most sensitive to 
cardiovascular risk factors may be already ill or dead. The absence of any significant 
difference in the number of deaths between different glucose tolerance categories may reflect 
this, as diabetes, abnormal glucose tolerance and metabolic syndrome should be important 
risk factors as regards death. The reason for this observation may also be that, unlike in 
proportional hazard analysis, time is not accounted for. The high prevalence of CVD in the 
study group indicates that there were still enough risk-sensitive subjects alive. 
 
This study addressed only men and similar studies on women or both genders have not yet 
been performed. In women, high testosterone values are connected with increased 
cardiovascular risk and metabolic syndrome (Apridonidze et al. 2004) and the effect of 
estrogen is stronger than in men, so the results could be different. 
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2.2 IGFBP-1 and SHBG in metabolic syndrome, diabetes and mortality 
 
In the present study we compared, in the same cohort, SHBG and IGFBP-1 as surrogate 
markers of glucose intolerance, metabolic syndrome, diabetes, cardiovascular risk and 
cardiovascular mortality. 
 
Individuals at an increased risk of type 2 diabetes, such as those with impaired glucose 
tolerance, identified via OGTTs, greatly need to be identified, as they form an important 
target group for diabetes prevention measures. Prevention of type 2 diabetes has been shown 
to be feasible. In prevention studies with goals of weight reduction, dietary changes and 
exercise, the overall incidence of diabetes was reduced by 58 percent (Tuomilehto et al. 2001, 
Knowler et al. 2002). Diabetes criteria have been updated at regular intervals, with the most 
recent one being given by the American Diabetes Association (ADA), where the oral glucose 
tolerance test is no longer recommended. However, using the fasting glucose criterion alone, 
subjects with isolated post-challenge hyperglycemia, consisting of one-sixth of diabetic 
patients, will remain undiagnosed (The DECODE Study Group 1999). 
 
As expected from their common regulators, such as insulin and thyroid hormones, both 
SHBG and IGFBP-1 concentrations were found to correlate inversely with glucose 
intolerance and metabolic syndrome in the same fashion. However, low SHBG concentrations 
were also associated with prevalent diabetes while low IGFBP-1 levels were not. Moreover, 
the association between SHBG levels and diabetes was less influenced by adjustment for 
BMI, suggesting that the effect of SHBG on glycemia was independent of obesity. However, 
because of the known association between SHBG and androgens, the present results on men 
point to a need for further studies on both genders, with a broader range of age. In a recent 
study of 20- to 39-year-old women with PCO, low SHBG concentrations were associated with 
metabolic syndrome (Apridonidze et al. 2004).  
 
Fasting hyperinsulinemia has been shown to increase the risk of fatal CVD (Hu et al. 2004). 
However, in one study concerning elderly men without diabetes, hyperinsulinemia alone did 
not appear to increase the risk (Oh et al. 2002). Older men with isolated post-challenge 
hyperglycemia have an increased mortality rate similar to that in other diabetic patients (The 
DECODE Study Group 1999). These patients cannot be identified without an OGTT, which is 
time-consuming and therefore not suitable for screening. As the basal SHBG level correlates 
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with two-hour glucose and insulin in the OGTT, it might provide useful information in those 
cases in which post-challenge hyperglycemia cannot be determined. 
 
This study is the first to show an association between coronary heart disease mortality and 
low SHBG levels in men, even though the association between low SHBG concentrations and 
abnormal glucose tolerance, metabolic syndrome or diabetes, conditions known to increase 
the risk of cardiovascular disease (Lakka et al. 2000), has also been observed in previous 
prospective studies (Goodman-Gruen and Barrett-Connor 1996, Haffner et al. 1996). The 
main difference between our study and a previous study showing no association between 
SHBG levels and CVD deaths (Goodman-Gruen and Barrett-Connor 1996) is that our study 
group was older and had more prevalent diseases at baseline. After adjustment for abnormal 
glucose tolerance the association between low SHBG levels and CVD or CHD mortality 
remained significant, indicating that glucose tolerance does not explain this association. 
Prevalent CVD is the strongest predictor of CVD mortality. In the present study the 
association between low SHBG levels and CHD or CHD mortality was no longer significant 
after adjustment for prevalent CVD. This is logical, because our study population consisted of 
elderly men and the prevalence of CVD was high at the outset. Nevertheless, SHBG levels 
did not differ between men with and without prevalent CVD at baseline. 
 
Low IGFBP-1 concentrations did not have the same association with CHD as low SHBG 
levels, so we were not able to confirm the findings of a recent investigation in which it was 
concluded that low baseline IGFBP-1 levels increase the risk of fatal ischemic heart disease 
among elderly predominantly nondiabetic men and women without prevalent cardiovascular 
disease (Laughlin et al. 2004). In our study group there were more diabetics and subjects with 
prevalent disease and the follow-up time was longer. The association between low IGFBP-1 
levels and an unfavorable cardiovascular risk profile (Harrela et al. 2000) is concordant with 
the results of this study. The unexplained association between high IGFBP-1 levels and 
mortality observed in the same population as ours at a younger age (Harrela et al. 2002) was 
no longer evident, possibly because the sensitivity of the aging population to risk factors is 
likely to change. 
 
The reasons for discordance between low SHBG and low IGFBP-1 levels with respect to 
cardiovascular and CHD death, despite their similar association with cardiovascular risk 
factors, are unclear. As insulin is the major regulator of both of these binding proteins, it is 
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possible that glucose metabolism does not explain the observed discordance. As sex 
hormones are also important regulators of SHBG, they may play a role here. 
 
Insulin increases ovarian androgen secretion in women (Nestler et al. 1997), whereas in men 
the association between testosterone and insulin concentrations is inverse, independent of age 
(Simon et al. 1992). The observed strong associations of low SHBG and low testosterone 
levels with abnormal glucose tolerance, metabolic syndrome and diabetes are concordant with 
somewhat higher insulin levels, as also observed by other investigators (Björntorp 1991, 
Simon et al. 1992). Prospective studies have also shown that low levels of SHBG and 
testosterone may predict the development of type 2 diabetes (Haffner et al. 1996). Whether 
the relationship between low testosterone levels and abnormal glucose metabolism is direct or 
indirect is not known, as the relationship between testosterone and insulin is complex (Wu et 
al. 2003). Previous studies, however, show no consistent association between testosterone 
concentrations and coronary heart disease or mortality (Muller et al. 2003, Wu et al. 2003). 
 
That both low SHBG and low testosterone concentrations were connected with abnormal 
glucose tolerance and cardiovascular risk factors in this study is somewhat surprising, as 
SHBG levels usually rise with age, whereas those of testosterone tend to fall. However, 
similar findings have been reported by other investigators (Goodman-Gruen and Barrett-
Connor 1996, Laughlin et al. 2004). In elderly men, total testosterone but not free 
bioavailable testosterone has been associated with the development of type 2 diabetes (Oh et 
al. 2002). The effect of androgen therapy could be either beneficial or harmful, as both high 
and low testosterone levels have been associated with a higher risk (Lindstedt et al. 1991) 
and, in animal studies, high-dose testosterone has been reported to worsen insulin resistance 
(Holmäng et al. 1992). In relatively small trials, androgen treatment has improved insulin 
sensitivity in middle-aged abdominally obese men (Marin et al. 1992, 1995), but the findings 
have not been consistent (Liu et al. 2003). The results of some studies suggest that exogenous 
administration of androgenic steroids to men or women leads to insulin resistance (Landon et 
al. 1962, Cohen et al. 1987). In other studies, administration of testosterone has improved 
insulin sensitivity, probably through improvements in body composition and a reduction in 
the levels of circulating nonesterified fatty acids (Marin et al. 1992, 1995). A window for 
optimal insulin sensitivity has been suggested, as both elevated and low testosterone 
concentrations can reduce body sensitivity to insulin (Björntorp 1991). The results of most 
studies suggest a less atherogenic lipid profile with increasing endogenous total testosterone 
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(Barrett-Connor 1995). Testosterone could be an independent risk factor for cardiovascular 
diseases or its effects may be mediated via other risk factors such as insulin levels. 
 
In conclusion, as initially hypothesized, low serum SHBG and IGFBP-1 concentrations may 
both indicate abnormal glucose tolerance and metabolic syndrome. Circulating levels of 
IGFBP-1 and SHBG also correlate with other known risk factors and surrogate markers of 
cardiovascular risk. Whereas IGFBP-1 levels show no association with cardiovascular 
morbidity or mortality, low SHBG concentrations are associated with increased 
cardiovascular mortality. 
 
2.3 IGFBP-3 and IGF-I in PROM and preterm delivery 
 
As both pregnancy and infection influence IGFBP-3 concentrations and protease activity 
(Langford et al. 1995, de Martino et al. 2000), and IGF-I levels have been found to decrease 
before delivery (Wang et al. 1991), it can be hypothesized that IGFBP-3 concentrations could 
be altered in PROM, chorioamnionitis and subsequent preterm birth. 
 
In term and preterm deliveries, many endocrinological changes have been found to be similar. 
For instance, the cascade of events leading to preterm birth represents a normal signal with 
inappropriate timing rather than an abnormal signal (Steer et al. 1990). This also applies to 
IGF-I and IGFBP-1, the serum levels of which are similar during term and preterm parturition 
(Wang et al. 1993). 
 
A number of changes occur in the IGF system during pregnancy. For instance, serum IGF-I 
(Wilson et al. 1982) and IGFBP-3 levels (Langford et al. 1995) rise with advancing 
gestational age. To our knowledge no data are available on these levels in women with PROM 
and preterm delivery, before regular uterine contractions appear. PROM invariably leads to 
preterm delivery (Cox et al. 1988), as also found in this study. We found that IGF-I and 
IGFBP-3 levels in women with PROM were similar to those in normal pregnancy, suggesting 
absence of their involvement in the pathogenesis of PROM or the pretem delivery that 
follows. We cannot exclude the possibility that antibiotics and/or corticosteroids given to 
women with PROM may affect serum IGF-I or IGFBP-3 levels. 
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Premature rupture of membranes is associated with chorioamnionitis in up to 70% of cases 
(Naeye et al. 1980). Therefore CRP concentrations were measured routinely to detect 
emerging intrauterine infection. Interestingly, the elevation of CRP levels had no association 
with the levels of either IGF-I or IGFBP-3. The reason may be that the emerging infection 
was local, because in generalized infection serum IGF-I and IGFBP-3 levels are low, as 
shown in children with perinatal human immunodeficiency virus infection and serious disease 
(de Martino et al. 2000). Low IGFBP-3 levels have also been found in other severely ill 
patients (Davies et al. 1991) and after surgery (Davenport et al. 1992). Therefore, IGF-I and 
IGFBP-3 may not serve as indicators of an acute phase reaction in chorioamnionitis. 
 
It is concluded that serum IGF-I and IGFBP-3 levels in women with PROM and preterm 
delivery, with and without intrauterine infection, do not differ from those in controls. This 
suggests that maternal serum IGF-I and IGFBP-3 do not appear to play any major role in 
preterm birth, and the changes in the IGF system are similar to those in normal birth. 
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CONCLUSIONS 
 
On the basis of the present work, the following conclusions can be drawn: 
 
1. The downregulation of IGFBP-1 and SHBG production caused by insulin and IGFs in 
hepatoma cells was found to be similar. This could indicate their similar ability to 
serve as possible markers of cardiovascular risk in insulin-resistant states. 
 
2. Estradiol stimulation resulted in no changes in hepatic cell IGFBP-1 secretion, while 
SHBG secretion was significantly increased.  These results suggest that the liver does 
not appear to contribute significantly to the elevated IGFBP-1 levels seen in response 
to high estrogen levels during ovarian stimulation. 
 
3. Insulin, IGF-I and IGF-II stimulated IGFBP-3 production in HepG2 cells. Sex 
hormones or the antiestrogen tamoxifen did not influence IGFBP-3 release at 
physiological concentrations. Cortisol had an inhibitory effect on IGFBP-3 
production. 
 
4. Subjects with metabolic syndrome or abnormal glucose tolerance had low serum 
SHBG and IGFBP-1 concentrations. Only SHBG (low level) was also associated with 
diabetes. The association between SHBG and glycemia was less dependent on obesity, 
vs. IGFBP-1. Both SHBG and IGFBP-1 levels also correlate with other known 
cardiovascular risk factors. Low SHBG levels were related to CVD mortality, whereas 
low IGFBP-1 levels were not. 
 
5. Serum IGF-I and IGFBP-3 levels remained unaltered in women with PROM. This 
suggests that maternal serum IGF-I and IGFBP-3 do not play any major role in 
preterm birth. 
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